309 related articles for article (PubMed ID: 20332474)
1. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
[TBL] [Abstract][Full Text] [Related]
2. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
3. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
4. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
6. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
Shimizu T; Hirano A; Kamimura M; Ogura K; Kim N; Watanabe O; Kinoshita J; Kimura K; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Nov; 30(11):4665-71. PubMed ID: 21115921
[TBL] [Abstract][Full Text] [Related]
8. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
[TBL] [Abstract][Full Text] [Related]
11. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
[TBL] [Abstract][Full Text] [Related]
12. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
[TBL] [Abstract][Full Text] [Related]
14. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y
Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
16. [A case of left breast cancer resulting in complete response by primary systemic therapy].
Fukuda T; Watanabe T; Kawahara M; Kodama H; Kikuchi S; Suzuki H
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1497-500. PubMed ID: 17876155
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Guarneri V; Frassoldati A; Bottini A; Cagossi K; Bisagni G; Sarti S; Ravaioli A; Cavanna L; Giardina G; Musolino A; Untch M; Orlando L; Artioli F; Boni C; Generali DG; Serra P; Bagnalasta M; Marini L; Piacentini F; D'Amico R; Conte P
J Clin Oncol; 2012 Jun; 30(16):1989-95. PubMed ID: 22493419
[TBL] [Abstract][Full Text] [Related]
18. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
[TBL] [Abstract][Full Text] [Related]
19. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
